Salicylic acid with zinc oxide
A topical combination of salicylic acid with zinc oxide, formulated as a paste or paint used as a keratolytic and protective preparation, including for warts, corns and hyperkeratotic skin conditions.
ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.
Clinical monograph
How it works
Salicylic acid acts as a keratolytic, softening and removing thickened keratin, while zinc oxide provides a mild astringent and protective barrier action that soothes and shields the surrounding skin.
Prescribing in practice
- Confine application to the affected lesion and protect adjacent healthy skin, as salicylic acid can cause irritation and erosion of normal skin.
- Avoid use on the face, anogenital region, broken or inflamed skin, and on lesions in patients with diabetes or peripheral arterial disease without specialist advice.
- The protective zinc oxide base may stain clothing and form an occlusive layer over the treated area.
Monitoring
No laboratory monitoring is required; review the treated lesion for response and excessive local irritation.
Counselling the patient
- Pare or file down softened skin between applications and apply the paste to the lesion only.
- Continue regular use over several weeks as directed.
- Discontinue and seek advice if marked soreness, redness or skin breakdown occurs.
Evidence & guidelines
Salicylic acid is the established keratolytic active, with zinc oxide long used as a soothing, protective excipient in dermatological pastes.
Reference: Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).
Related
Curated clinical cross-links plus same-class fallbacks.
- Tumor Lysis Syndrome Risk (Cairo-Bishop) · Oncological Emergency
- FAST Exam Protocol — Focused Assessment with Sonography in Trauma · Trauma
- Urine Anion Gap · Acid-Base
- Bicarbonate Deficit Calculator · Acid-Base
- Delta Ratio for Mixed Acid-Base Disorders · Acid-Base
- Expected PaCO₂ in Metabolic Acidosis (Winter's Formula) · Acid-Base
- Suspicious Pigmented Lesion — Melanoma Pathway · NICE NG14 2015 / BAD
- Cellulitis and Erysipelas · NICE NG141 2019 / CREST
- Psoriasis — Severity Assessment and Step-Up Therapy · NICE NG153 2019 / BAD
- Atopic Eczema — Assessment and Step-Up Therapy · NICE NG95 2023
- Urticaria and Angioedema · BSACI / EAACI Guidelines 2022
- Acne Vulgaris — Grading and Treatment · NICE NG198 2021 / BAD